Previous close | 4.0000 |
Open | 4.2600 |
Bid | 3.5000 |
Ask | 5.9000 |
Strike | 12.50 |
Expiry date | 2024-05-17 |
Day's range | 4.2000 - 4.2600 |
Contract range | N/A |
Volume | |
Open interest | 31 |
Achieved Total Q1 2024 Revenues of $98.5 Million, a 15.4% YoY Increase, Underscored by Exceptional Execution and Continued Demand for Commercial Products FIRDAPSE® Q1 2024 Net Product Revenues of $66.8 Million, a 16.2% YoY Increase Robust Revenue Momentum for FIRDAPSE® Successfully Commenced the U.S. Launch of AGAMREE® on March 13, 2024 Reported AGAMREE® Q1 2024 Net Product Revenues of $1.2 Million for the First Two Weeks of Commercial Availability Early AGAMREE® Launch Indicators Highlight Prom
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Catalyst (CPRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.